Market Research Logo

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016’, provides in depth analysis on Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted pipeline therapeutics.

The report provides comprehensive information on the Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.
  • Updated report will be delivered in 48 hours of order confirmation.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)
    • The report reviews Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics and enlists all their major and minor projects
    • The report assesses Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news and deals related to Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand the targeted therapy areas and indications for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)
    • Identify the use of drugs for target identification and drug repurposing
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) development landscape
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Overview
Therapeutics Development
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Stage of Development
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Therapy Area
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Indication
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Companies
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Universities/Institutes
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Companies Involved in Therapeutics Development
Amgen Inc.
Bristol-Myers Squibb Company
Chong Kun Dang Pharmaceutical Corp.
Japan Tobacco Inc.
Kowa Company, Ltd.
Merck & Co., Inc.
Pfizer Inc.
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Drug Profiles
AMG-899 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anacetrapib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-795311 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-519 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dalcetrapib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HL-16 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-04445597 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Dormant Projects
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Discontinued Products
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Featured News & Press Releases
Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial
Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics
Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial
Nov 13, 2015: Merck Provides Update on REVEAL Outcomes Study
Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery
Jun 03, 2015: Dezima Pharma’s CETP Inhibitor, TA-8995, Phase 2b (TULIP) Study Results Published in The Lancet
Jan 12, 2015: A World First - Discovery of a personalized therapy for cardiovascular disease
Nov 13, 2014: Dezima Pharma Announces Complete Enrolment of CETP Inhibitor TA-8995 Study in Subjects With Isolated, Elevated Lipoprotein(a) Levels
Aug 29, 2014: Dezima Reports Positive Results in its Phase 2b TULIP Trial with CETP Inhibitor TA-8995 in Dyslipidemia
Jul 08, 2014: Dezima Pharma extends clinical development program for its CETP Inhibitor TA-8995
Jan 13, 2014: Dezima Pharma Completes Patient Enrolment for TULIP Phase 2B Study with CETP Inhibitor TA-8995
Aug 29, 2013: Dezima Pharma initiates Phase 2b TULIP study on CETP inhibitor program DEZ-001
Nov 05, 2012: Roche's Dalcetrapib Increases HDL Levels But Fails To Reduce Risk Of Cardiovascular Events, Study Finds
Aug 26, 2012: Merck Provides Update On Anacetrapib Development Program
May 07, 2012: Roche Provides Update On Phase III Study Of Dalcetrapib
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Amgen Inc., H2 2016
Pipeline by Bristol-Myers Squibb Company, H2 2016
Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
Pipeline by Japan Tobacco Inc., H2 2016
Pipeline by Kowa Company, Ltd., H2 2016
Pipeline by Merck & Co., Inc., H2 2016
Pipeline by Pfizer Inc., H2 2016
Dormant Projects, H2 2016
Discontinued Products, H2 2016
Discontinued Products (Contd..1), H2 2016
Discontinued Products (Contd..2), H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report